Vuno's AI-powered fundus reading solution approved for sale in Taiwan

Vuno Inc., a South Korean artificial intelligence-powered medical solutions provider, said on Tuesday that Vuno Med-Fundus AI has received marketing license approval from the Taiwan Food and Drug Administration (TFDA).

The AI solution provides major findings for the diagnosis of retinal diseases by locating abnormalities such as drusen, hemorrhage and hard exudate, detecting the abnormalities in fundus images and presenting patient reports.

The AI solution also earned a marketing license from Singapore's Health Sciences Authority (HSA) in September of this year.

Including Fundus AI, Vuno has received TFDA’s marketing approvals for its three medical solutions in a bid to expand its business in the Asia-Pacific region.

It received licenses for Vuno Med-Chest X-ray, which assists in readings of common thoracic abnormalities on chest radiographs and Vuno Med-BoneAge, a diagnostic solution that provides assessments of bone age on hand X-ray images.

In January 2021, Vuno signed an exclusive distributorship agreement with Taiwan’s CHC Healthcare Group for its four AI products, the three solutions with TFDA’s approval and Vuno Med-LungCT AI.

CHC Healthcare, a leading distributor of medical equipment and pharmacy chain operator in Taiwan, is in charge of Vuno products’ local licensing, marketing, promotion and sales.

Write to Ji-Hyun Lee at bluesky@hankyung.com
Jihyun Kim edited this article.